Adults

Researchers are evaluating the "One All" curriculum, which uses the sport Ultimate Frisbee to improve mental health resilience among young tribal people in two communities in South India. The study aims to see if this intervention is feasible and acceptable while assessing its effectiveness in building resilience and mental well-being. The research involves young tribal adults aged 12 to 25 years from Gudalur in Tamil Nadu and BR Hills in Karnataka. The intervention includes a three-year curriculum delivered by trained community facilitators who adapt the program to fit local needs. Participants attend two or more sessions each week, each lasting about one and a half hours. Sessions involve warm-up activities, drills, ultimate frisbee games with modified rules, and group discussions called spirit circles. The program focuses on developing skills such as self-management, social awareness, empathy, identity building, and conflict resolution. Participants undergo assessments before the program starts, after 12 months, and after 18 months. These include questionnaires measuring resilience (Child Youth Resilience Measure and Connor-Davidson Resilience Scale), mental health (GHQ12), and self-efficacy. Researchers will track attendance and reflections from sessions but will not access medical records. The study involves a baseline interview collecting socioeconomic data and assigns participants codes to protect privacy. Total participation lasts at least 18 months to evaluate outcomes.

Researchers are conducting the 100-Year Human Aging Study, an observational trial designed to follow participants over their lifespans to investigate which health measurements can predict mortality, serious diseases, and functional disability. The study aims to validate many longevity measures that currently lack prospective evidence by tracking physiological, cognitive, social, and environmental factors that change with aging. This research will generate important data to improve understanding of aging and longevity medicine. Participants undergo comprehensive multi-system clinical screenings including tests like cardiopulmonary exercise testing, body composition assessment by DEXA, echocardiography, electrocardiography, spirometry, neurocognitive testing, sensory assessments, metabolic testing, and detailed medical and social histories. The study allows for different levels of participation, from single tests to full two-visit screening batteries, and encourages repeat testing to capture health changes over time. During the study, participants receive individualized reports including investigational estimates of biological age and predicted cause of death. Researchers collect data on mortality, serious health events, chronic diseases, functional ability, and lifestyle changes through periodic follow-up over many years, potentially up to 100 years. This extensive data collection helps evaluate how well these measurements predict aging outcomes. All data are stored in raw form for future analysis and participants are supported with ongoing contact and opportunities for repeat assessments.

Researchers are developing advanced four-dimensional magnetic resonance imaging (4D-MRI) techniques to create detailed, moving images of the lungs and liver in adults. This imaging method produces three-dimensional movies that capture organ motion during breathing, which is important for improving radiation therapy planning for lung and liver cancer patients. The study aims to overcome challenges in current imaging methods to better target tumors that move with respiration. The study includes two main parts: technical development of ultra-quality 4D-MRI in healthy volunteers and evaluation of the technique in cancer patients. This involves creating a new MRI pulse sequence and image reconstruction process to achieve high spatial and temporal resolution with minimal motion artifacts. Researchers will compare the new 4D-MRI method to existing imaging and registration techniques in both healthy volunteers and patients with lung or liver tumors undergoing radiation therapy. Participants will undergo a single imaging session lasting up to two hours involving 4D-MRI scans. Healthy volunteers and cancer patients will be assessed to measure image quality and accuracy of motion modeling. The study will monitor how well the 4D-MRI technique captures tumor movement compared to current methods. The total participation time is limited to the imaging session, with no long-term follow-up mentioned.

Researchers are evaluating the safety, tolerability, and how the body processes SPH9788 tablets in healthy adult volunteers aged 18 to 45 years. This randomized, double-blind, placebo-controlled Phase I study aims to understand the effects of single and multiple increasing doses of SPH9788 in a healthy Chinese population. The study is sponsored by Shanghai Pharmaceuticals Holding Co., Ltd and focuses on monitoring any treatment-emergent or serious adverse events during the trial period. Participants will receive either SPH9788 tablets or a matching placebo, both given orally. The study involves administering single and multiple ascending doses to assess safety and pharmacokinetics, including measures such as time to maximum concentration (Tmax), maximum concentration (Cmax), and area under the curve (AUC). These treatments are carefully monitored over approximately one year. During the study, volunteers will undergo regular assessments to track safety and drug processing in the body. Researchers will observe adverse events and collect pharmacokinetic data through blood tests at set intervals. Participants must follow lifestyle restrictions and contraceptive use during the trial and for six months afterward. The total duration of participation includes screening, treatment, and follow-up to ensure thorough safety evaluation.

Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of SV003 in healthy adult participants aged 18 to 45 years. This randomized, double-blind, placebo-controlled Phase I clinical trial aims to understand how SV003 behaves in the body and its safety profile in individuals without active or chronic diseases. The study is sponsored by Shanghai Synvida Biotechnology Co., Ltd. and focuses on healthy volunteers. Participants will receive a single dose of either the study drug SV003 or a placebo. The trial uses a randomized assignment to one of these two groups and includes a double-blind design, meaning neither participants nor researchers know who receives which treatment during the study. The dosing involves a single administration, after which participants will be monitored. During the approximately three-month study period, participants will undergo regular assessments to track any treatment-emergent adverse events. Researchers will also measure pharmacokinetic parameters such as peak plasma concentration, peak time, area under the plasma concentration curve, half-life, and immunogenicity. Participants will be closely monitored for safety and tolerability throughout the study to gather comprehensive data on SV003's effects.

Researchers are evaluating the safety, tolerability, and how the body processes a new medicine called CPV-104. This medicine is designed to regulate the complement system, which can be overactive in a rare kidney condition called C3 glomerulopathy (C3G). The study includes both healthy adults and adults with C3G to understand how CPV-104 affects different groups and to check for any immune reactions or side effects. The trial has two parts. In the first part, healthy volunteers receive a single intravenous dose of CPV-104 or a placebo in a randomized, double-blind setting. In the second part, patients with C3G receive four weekly intravenous doses of CPV-104 without placebo. Dose escalation is allowed if the treatments are well tolerated. All doses are given by healthcare professionals, and a Safety Review Committee monitors safety data to decide on progressing with doses and groups. Participants will be closely monitored throughout the study with checks for side effects, blood and urine tests, ECGs, vital signs, and blood samples to measure drug levels and antibodies. For patients with C3G, kidney function is also observed. The main focus is on safety rather than effectiveness. The study tracks serious and severe drug reactions up to Day 29 for healthy volunteers and Day 50 for C3G patients. Participation includes a screening period and follow-up assessments to ensure safety and gather important information about CPV-104.

Researchers are evaluating how a combined program of aerobic and resistance exercises along with cognitive training affects brain function in older adults aged 60 and above. The study focuses on people who are sedentary and may or may not have cardiovascular risk factors like diabetes, high blood pressure, or high cholesterol, conditions known to impact memory and attention. This trial aims to compare the effects of physical exercise alone versus combined physical and cognitive training on thinking skills and brain health. The trial includes three groups: one group will do both cognitive and physical training, another will do only aerobic and resistance exercises, and the third group will perform stretching and toning exercises as an active control. Each group participates in three sessions per week for 46 weeks, with options to train at home or at a center. The physical exercise sessions include warm-up, moderate to vigorous aerobic activity monitored by heart rate, and resistance training, while cognitive training involves computer-based memory and attention tasks. Participants will undergo assessments at the start and after 12 months to measure changes in general cognition, processing speed, executive functions, and memory. Brain imaging and blood flow measures will also be evaluated to observe changes in brain structure and function. Throughout the study, participants will be monitored for exercise intensity and adherence. The total study duration covers 12 months, with safety and cognitive outcomes closely tracked to understand the impact of these interventions.

Researchers are evaluating a computer-based cognitive rehabilitation program called Enhancing Memory in Daily Life (E-MinD Life) aimed at delaying functional decline related to cognitive changes in Chinese healthy older adults, those with memory complaints, mild cognitive impairment (MCI), and mild dementia. This pilot study is conducted in Hong Kong and includes participants without depression or other clinical conditions affecting cognition. The study uses a randomized controlled design to assess the feasibility and benefits of the E-MinD Life program. The trial has two groups: one receives the E-MinD Life Semantic program, which teaches memory strategies applied to 12 daily activities over 9 weeks with weekly sessions led by healthcare professionals and family-assisted home practice. The other group receives cognitive stimulation through visual and auditory memory activities with a similar schedule. Both interventions include one 45-minute individual session and two 30-minute home sessions weekly. Participants will attend sessions either face-to-face or online, with family or carers involved for support and observation. Researchers will assess acceptability at the end of the 9-week intervention and measure feasibility through attendance rates. Cognitive and daily living abilities will be evaluated using various tests from enrollment to intervention end. The total participation includes these assessments and intervention monitoring over 9 weeks.

Researchers are studying the safety, how the body processes, and the effects of the drug RO7875913 in healthy adult volunteers. This Phase I clinical trial aims to better understand the drug's behavior in the body and monitor any side effects or immune responses it may cause. The study is sponsored by Genentech, Inc. and focuses on healthy adults aged 18 to 65 years. Participants will be randomly assigned to receive either the study drug RO7875913 or a placebo. The study uses a dose-escalation design to evaluate different doses of RO7875913. The treatment period lasts up to approximately three months, during which various drug concentrations and immune responses are measured. The study also aims to identify the recommended dose for future studies. During the trial, participants will undergo safety monitoring with assessments for adverse events, blood tests to measure drug levels and immune markers, and evaluations of pharmacodynamic markers. The main outcome is tracking any adverse events up to about three months. Participants will be followed closely throughout the treatment and observation period, which includes laboratory testing up to Day 76. The total participation duration depends on the study schedule and dose escalation.

Adults with cerebral palsy (CP) often face difficulties in accessing exercise programs tailored to their needs due to limited mobility, lack of suitable options, and restricted physiotherapy access. Regular exercise is important for improving physical health, mental well-being, and overall quality of life, but many adults with CP do not have structured opportunities for physical activity. This research aims to evaluate the feasibility of delivering an accessible online exercise program designed specifically for adults with CP, focusing on demand, practicality, acceptability, and potential benefits to physical, mental, and social health. The study will recruit 60 adults with CP who will be randomly assigned to one of two groups. One group will participate in an 8-week online exercise and education program that includes weekly online exercise classes targeting strength, balance, and range of movement, along with educational materials covering topics like exercise, nutrition, fatigue, bone health, pain management, mental health, and sleep. The other group will receive the same educational materials over 8 weeks without the exercise classes and will be informed about the home exercise program after the intervention period. Participants will be monitored throughout the study with data collected on attendance, completion rates, engagement with exercises, and any adverse events. Health-related surveys will be completed before and after the program to assess changes in physical function, mobility, pain, fatigue, sleep, self-efficacy, depression, and participation. Selected participants will also provide feedback through interviews. The study duration includes rolling recruitment over 1.2 years and outcome measurements over 2 years, aiming to support the development of effective online exercise programs for adults with CP.